What is BridgeBio Oncology Therapeutics Quick Ratio?
BridgeBio Oncology TherapeuticsBBOT +3.70%12 Quick Ratio is 6.16 as of Mar. 2026, which is at its 10-year median of 6.16. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 1,410 Biotechnology companies, BridgeBio Oncology Therapeutics ranks better than 65.67% on this metric.
BridgeBio Oncology Therapeutics has a quick ratio of 6.16. It generally indicates good short-term financial strength.
The historical rank and industry rank for BridgeBio Oncology Therapeutics's Quick Ratio or its related term are showing as below:
BBOT'
s Quick Ratio Range Over the Past 10 Years
Min: 0.23 Med: 6.16 Max: 13.33
Current: 6.16
During the past 3 years, BridgeBio Oncology Therapeutics's highest Quick Ratio was 13.33. The lowest was 0.23. And the median was 6.16.
BBOT's Quick Ratio is ranked better than 65.67% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs BBOT: 6.16
BridgeBio Oncology Therapeutics (NAS:BBOT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BridgeBio Oncology Therapeutics Quick Ratio Related Terms
BridgeBio Oncology Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's Quick Ratio falls into.
BridgeBio Oncology Therapeutics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics (BBOT) has a Quick Ratio of 6.16 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BridgeBio Oncology Therapeutics and its competitors. This is near median its historical median of 6.16. Over the past decade, BridgeBio Oncology Therapeutics' Quick Ratio has ranged from 0.23 to 13.33. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #484 out of 1410 companies in the Biotechnology industry, placing it in the top 34.3%.
Is BridgeBio Oncology Therapeutics' Quick Ratio too high?
BridgeBio Oncology Therapeutics' current Quick Ratio of 6.16 is near median its 10-year median of 6.16. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 13.33. The Biotechnology industry median Quick Ratio is 3.60. BridgeBio Oncology Therapeutics' value of 6.16 is 71.1% above this industry median. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #484 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Quick Ratio compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #484 out of 1410 companies for Quick Ratio. This puts BridgeBio Oncology Therapeutics in the upper half of its industry. The industry median Quick Ratio is 3.60. BridgeBio Oncology Therapeutics' value of 6.16 is 71.1% above this benchmark. Historically, BridgeBio Oncology Therapeutics' own Quick Ratio has ranged from 0.23 to 13.33 over the past decade. While the company's 10-year median is 6.16 vs. the industry median of 3.60, BridgeBio Oncology Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Oncology Therapeutics's current Quick Ratio of 6.16 is 71.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current Quick Ratio is 6.16, which is near median its own 10-year median of 6.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Quick Ratio of 6.16. The current Quick Ratio is 6.16, which is near median its 10-year median of 6.16 and 71.1% above the Biotechnology industry median of 3.60. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Quick Ratio is 6.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Business Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
